SUNLINK HEALTH SYSTEMS INC Form SC 13D/A March 25, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 6)*
SunLink Health Systems, Inc.

(Name of Issuer)

Common Stock, without par value

(Title of Class of Securities) **86737U102**

(CUSIP Number)
Jared S. Bluestein
Berggruen Holdings North America Ltd.
1114 Avenue of the Americas, 41st Floor
New York, New York 10036
(212) 380-2235

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
-with a copy to-

Clifford E. Neimeth, Esq. Greenberg Traurig, LLP The MetLife Building 200 Park Avenue New York, NY 10166 (212) 801-9200 March 24, 2008

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box b.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 86737U102 NAME OF REPORTING PERSONS 1 Berggruen Holdings North America Ltd. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) þ (b) o SEC USE ONLY 3 SOURCE OF FUNDS (SEE INSTRUCTIONS) 4 00CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 o CITIZENSHIP OR PLACE OF ORGANIZATION 6 British Virgin Islands **SOLE VOTING POWER** 7 NUMBER OF -0- (See Item 5) **SHARES** SHARED VOTING POWER

BENEFICIALLY OWNED BY

704,039 (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** -0- (See Item 5) WITH SHARED DISPOSITIVE POWER 10 704,039 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

2

14

CO

SCHEDULE 13D

CUSIP No. 86737U102 NAME OF REPORTING PERSONS 1 Berggruen Holdings Ltd. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) þ (b) o SEC USE ONLY 3 SOURCE OF FUNDS (SEE INSTRUCTIONS) 4 00CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 o CITIZENSHIP OR PLACE OF ORGANIZATION 6 British Virgin Islands **SOLE VOTING POWER** 7 NUMBER OF -0- (See Item 5) **SHARES** SHARED VOTING POWER BENEFICIALLY

OWNED BY

704,039 (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** -0- (See Item 5) WITH SHARED DISPOSITIVE POWER 10 704,039 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

3

14

CO

SCHEDULE 13D

CUSIP No. 86737U102 NAME OF REPORTING PERSONS 1 Tarragona Trust CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) þ (b) o SEC USE ONLY 3 SOURCE OF FUNDS (SEE INSTRUCTIONS) 4 00CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 o CITIZENSHIP OR PLACE OF ORGANIZATION 6 British Virgin Islands **SOLE VOTING POWER** 7 NUMBER OF -0- (See Item 5) **SHARES** SHARED VOTING POWER BENEFICIALLY

OWNED BY

704,039 (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** -0- (See Item 5) WITH SHARED DISPOSITIVE POWER 10 704,039 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

4

14

SCHEDULE 13D

CUSIP No	o. 86737	U102
1	NAME OF F	REPORTING PERSONS gruen
2	CHECK THE	E APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
3	SEC USE O	NLY
4	SOURCE OF	F FUNDS (SEE INSTRUCTIONS)
5	CHECK BO ITEMS 2(d)	X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO OR 2(e)
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States	
NII IMDE	7 ED OE	SOLE VOTING POWER
SHAF BENEFIC	RES CIALLY 8	-0- (See Item 5) SHARED VOTING POWER
OWNE	D BY	704,039 (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** -0- (See Item 5) WITH SHARED DISPOSITIVE POWER 10 704,039 (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

5

14

IN

SCHEDULE 13D

CUSIP No. 86737U102 NAME OF REPORTING PERSONS 1 Resurgence Health Group, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) þ (b) o SEC USE ONLY 3 SOURCE OF FUNDS (SEE INSTRUCTIONS) 4 00CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 o CITIZENSHIP OR PLACE OF ORGANIZATION 6 Georgia, United States **SOLE VOTING POWER** 7 NUMBER OF -0- (See Item 5) **SHARES** SHARED VOTING POWER BENEFICIALLY

OWNED BY

-0- (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** -0- (See Item 5) WITH SHARED DISPOSITIVE POWER 10 -0- (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

6

14

SCHEDULE 13D

CUSIP No. 86737U102 NAME OF REPORTING PERSONS 1 Philip H. Eastman, III CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) þ (b) o SEC USE ONLY 3 SOURCE OF FUNDS (SEE INSTRUCTIONS) 4 00CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 o CITIZENSHIP OR PLACE OF ORGANIZATION 6 **United States SOLE VOTING POWER** 7 NUMBER OF 100 (See Item 5) **SHARES** SHARED VOTING POWER BENEFICIALLY

OWNED BY

-0- (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** 100 (See Item 5) WITH SHARED DISPOSITIVE POWER 10 -0- (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

7

14

IN

SCHEDULE 13D

CUSIP No. 86737U102 NAME OF REPORTING PERSONS 1 Anne S. Thompson CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) 2 (a) þ (b) o SEC USE ONLY 3 SOURCE OF FUNDS (SEE INSTRUCTIONS) 4 00CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 o CITIZENSHIP OR PLACE OF ORGANIZATION 6 **United States SOLE VOTING POWER** 7 NUMBER OF -0- (See Item 5) **SHARES** SHARED VOTING POWER BENEFICIALLY

OWNED BY

-0- (See Item 5)

Edgar Filing: SUNLINK HEALTH SYSTEMS INC - Form SC 13D/A **EACH** SOLE DISPOSITIVE POWER 9 REPORTING **PERSON** -0- (See Item 5) WITH SHARED DISPOSITIVE POWER 10 -0- (See Item 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 704,139 (See Item 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 12 o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 9.4% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

8

14

IN

Explanatory Note: This Amendment No. 6 relates to and amends the Statement of Beneficial Ownership on Schedule 13D of Berggruen Holdings North America Ltd., a British Virgin Islands (_BVI_) business company, Berggruen Holdings Ltd., a BVI business company, Tarragona Trust, a BVI trust, Nicolas Berggruen, a United States citizen, Resurgence Health Group, LLC, a Georgia limited liability company (_Resurgence_), Philip H. Eastman, III, a United States citizen, and Anne S. Thompson, a United States citizen (each, a _Reporting Person_ and collectively, the _Reporting Persons), initially filed jointly by the Reporting Persons with the Securities and Exchange Commission (the _SEC_) on November 7, 2007 and as amended by Amendment Nos. 1, 2, 3, 4 and 5 thereto filed jointly by the Reporting Persons with the SEC on December 10, 2007, January 14, 2008, January 22, 2008, February 1, 2008 and March 3, 2008, respectively (as amended, the _Statement_), with respect to the Common Stock, without par value (the _Common Stock_), of SunLink Health Systems, Inc., an Ohio corporation (the _Issuer_).

Items 4 and 7 of the Statement are hereby amended to the extent hereinafter expressly set forth. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Statement. **Item 4. Purpose of Transaction.**

Item 4 of the Statement is hereby amended to add the following:

On March 24, 2008, Resurgence submitted to the Chairman of the Special Committee of the Board a letter dated March 24, 2008, a copy of which is filed herewith as <u>Exhibit 4</u> and is incorporated herein in its entirety by reference.

The Reporting Persons intend to review their investment in the Common Stock on a continuing basis and, from time to time, may engage in further discussions with the Issuer's senior executives and members of the Board concerning the foregoing. The Reporting Persons also intend to communicate with other shareholders of the Issuer, industry analysts and other constituents concerning the foregoing and to express their views of the Issuer, its management and the Board.

Depending on various factors including, without limitation, the Issuer s financial performance and strategic direction, the outcome of the discussions and actions referenced above, price levels of the Common Stock, developments affecting the Issuer and its prospects, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future consider and take various courses of action with respect to the Issuer, its Board and its management and their investment in the Issuer, and the Reporting Persons may exercise any and all of their respective rights as shareholders of the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock or selling some or all of their shares of Common Stock, engaging in short selling of or any hedging or similar transactions with respect to the Common Stock, encouraging the Issuer to take action to maximize shareholder value through one or more strategic transactions and/or otherwise changing its intention with respect to any and all matters referred to in Item 4 of Schedule 13D.

Except as set forth in the Statement and in this Amendment No. 6, none of the Reporting Persons has any present plans or proposals that relate to or would result in any of the matters referred to in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 7. Materials to be Filed as Exhibits.

Exhibit 1	Joint Filing Agreement among the Reporting Persons, dated November 7, 2007 (incorporated by reference to Exhibit 1 to the Statement filed by the Reporting Persons with respect to the Issuer on November 7, 2007).
Exhibit 2	Limited Power of Attorney, dated June 23, 2006, given by Maitland Trustees Limited, as trustee of the Tarragona Trust, to Jared Bluestein (incorporated by reference to Exhibit 2 to the Statement filed by the Reporting Persons with respect to the Issuer on November 7, 2007).
Exhibit 3	Limited Power of Attorney, dated August 10, 2007, given by Nicolas Berggruen to Jared Bluestein (incorporated by reference to Exhibit 3 to the Statement filed by the Reporting Persons with respect to the Issuer on November 7, 2007).
Exhibit 4	Letter dated March 24, 2008 from Resurgence to the Chairman of the Special Committee of the Board of Directors of the Issuer.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: March 25, 2008

Berggruen Holdings North America Ltd.

By: /s/ Jared S. Bluestein

Name: Jared S. Bluestein

Title: Director

Berggruen Holdings Ltd.

By: /s/ Jared S. Bluestein

Name: Jared S. Bluestein

Title: Director

Tarragona Trust

By: Maitland Trustees Limited, as Trustee

By: /s/ Jared S. Bluestein

Name: Jared S. Bluestein Title: Authorized Signatory

*

Nicolas Berggruen

Resurgence Health Group, LLC

By: /s/ Philip H. Eastman, III

Name: Philip H. Eastman, III Title: Chief Executive Officer

/s/ Philip H. Eastman, III

Philip H. Eastman, III

/s/ Anne S. Thompson

Anne S. Thompson

^{*} The undersigned, by signing his name hereto, does sign and execute this Statement pursuant to the Limited Power of Attorney executed by Nicolas Berggruen filed as Exhibit 3 to this Statement.

Dated: March 25, 2008	*By:	/s/ Jared S. Bluestein, Attorney-in-Fact Jared S. Bluestein
	11	
t;text-autospace:none;">Heineken		
Heineken and Coors brands in Canada		
Risk they go alone or team with other Cdn brew	ver	
\Rightarrow		
SAB/Miller		
Moderate risk in Canada		
US marginalized		

Heineken

\Rightarrow
Anheuser-Busch
Heineken brand in Canada
Increased domestic competition or pricing pressure
\Rightarrow
Femsa
Modelo brands in Canada
Modelo brands in Canada
Risk to Molson is not only immediate impact, but loss of choice and options: Molson must preempt the outcome
7

Molson and Coors: The Right Combination

Brazil

[LOGO] & [LOGO] [GRAPHIC]

North America s oldest brewer 13th largest brewer in the world Leading position in Canada; opportunity in Established in 1873 by Adolph Coors 8th largest brewer in the world Leading brands in US and UK beer growth

markets

Rich Brewing Heritage, Experienced Management, Leading Brands

Merger Improves Likelihood of Regaining the Vision		
value	To secure the current commercial relationship with Coors, which represents 20% of Molson s total shareholder	
	To identify and obtain \$175 million in synergies, which would not be available to Molson otherwise:	
	Capitalizes on Molson s proven track record in delivering cost savings	
Canadi	To be able to drive top line sales in Canada through increased marketing investments behind Molson an and Coors Light	
from th	To reduce the financial impact of Brazil, allowing Molson shareholders greater time to receive the payback e Brazil investment	
new ca	To expand brewing operations in Montreal and Toronto by adding 2M hl of beer: new jobs supported with pital investment	
	9	

Makes Perfect Sense

Creates top-5 brewer with the operational scale to succeed in the global brewing industry
Strong market positions in some of the world s largest beer markets
Broader geographic base provides diversified sources of revenue, profit and cash
Experienced management team to ensure smooth integration and capitalize on growth opportunities
126 years of consumer industry experience
Proven integration skills
Natural strategic and cultural fit
Complementary product lines and operational geography
Existing strong working relationships
Common values, operating philosophies and heritages
Objective is to deliver top quartile shareholder returns

With Broad Scope & Scale		
Pro forma LTM net sales and EBITDA(1) of approximately US\$6.0 billion and US\$1.0 billion, respectively		
Combined 2003 volume of 60M hl/51M US bbls		
Combined product portfolio of more than forty brands		
[GRAPHIC]		
Distribution and/or licensing agreements with leading international brewers including Heineken, Grolsch, FEMSA, and Grupo Modelo		
(1) EBITDA represents earnings before interest, tax, depreciation and amortization.		
11		

Enhanced Platform in Developed Markets, Balanced Emerging Market Exposure
Strong positions in world s highest margin beer markets
Growth opportunities through underdeveloped regions/brands in mature markets and Brazil
2003 Volume 60M hl
[CHART]
LTM Net Sales US\$6B
[CHART]
LTM EBITDA US\$1B
[CHART]
(1) Includes Coors America s segment
(2) Includes Coors Europe segment
Strong geographically diversified company
12

With Leading Positions in Key Markets

			All Brand Market	All Brands	
Country	Top Brand	Rank	Share	Rank	
Canada	[GRAPHIC]	#1	43%	#1	
United Kingdom	[GRAPHIC]	#1	21%	#2	
United States	[GRAPHIC]	#3	11%	#3	
Brazil	[GRAPHIC]	#3	11%	#3	

Source: Datamonitor and Brewers of Canada (2003)

Strong brands in some of the world s largest beer markets

Coors Growth Model		
Leverage strength in high-share markets to grow more strong markets		
U.S. st:distribution, 2 nd : invest with distributors (50/205)		
Drivers: YAM, Hispanic programming, trial channels		
U.K. Scotland, SE/London, Carling X-Cold, Coors Fine Light		
International:		
Mexico: Export with FEMSA sales/distribution		
China: largest global beer market (volume), 20 cities (no breweries)		
Japan: Zima (Coors sales force)		
Reduce costs to reinvest against the front-end, grow returns on capital		

Coors Performance Overview: 2003		
	Improvements made in key areas of the business	
	Continued investments in future growth	
	Generated cash and exceeded debt repayment goals	
	Strengthened financial position; strengthened and grew returns on capital	
	In the most recent fiscal year, Coors emerged a stronger company in a very tough year.	
	15	

Coors A	mericas Segment: Coors Brewing Company
	Continued strong U.S. pricing environment
	Share maintained in a flat, highly competitive beer market
	Refined marketing strategy gaining traction with key demographic groups
account	Sales organization strengthened and making progress in key markets (Hispanic) and channels (national ts, convenience stores)
years)	Proven track record in improving efficiency and reducing cost of U.S. operations (Goal: US\$100mm in next 5
	Consistently able to generate cash, pay down debt
	Canada: 7+% volume growth; 28% pretax income growth in 2003
	16

Coors Europe Segment: Coors Brewers Limited
Carling #1 U.K. beer brand 30% larger than #2 brand
Significant improvements in balancing volume and margins
Achievements in productivity and cost reductions (new packaging lines in Burton, outsourcing of kegs and pub servicing)
Long-term market trends play to Coors strengths: growth in lagers, move toward off-premise/chains, where brand building is key
2003: Grew volume 7% and share 1.2 percentage points to 20.3%
17

In the UK, Consistent Strong Growth in Both the On-Trade				
Owned Brand Market Share - On Trade				
[CHART]				
On-Trade (~65% of CBL volume)				
18				

and the Off-Trade
Owned Brand Market Share - Off-Trade
[CHART]
Off-Trade (~35% of CBL volume)
19

Balanced Board & Management Team

Molson		Chairman		Coors
Independent		E. Molson		Independent
Molson Independent		Office of Synergies & Integration		Coors Independent
Molson	Vice Chairman		CEO	Coors
Independent	D. J. O Neill		L. Kiely	Independent
Molson				Coors
Family				Family
	Elected	Elected	Elected	Coors
	Independent	Independent	Independent	Family
		20		

Synergies

	Expected (US\$		% of Pro Forma Cost Base
Brewery Network Optimization	\$	60	1.1%
Procurement Savings		43	0.8
SG&A		40	0.8
Best In Class Savings		12	0.2
Organizational Design		10	0.2
Other		10	0.2
Total	\$	175	3.3%

Molson Coors has identified a clear path to substantial synergies

Profit Impact and Estimated Timing
Impact on EBITDA of 100% Synergies
[CHART]
Expected Timing of Synergies
[CHART]
50% of synergy capture to occur in the first 18 months
22

Significant Opportunity for Margin Expansion

			TDA to Net Sales			Molson Without	With 100%
	CY99	CY00	CY01	CY02	CY03	Synergies	Synergies
Molson*	18.3%	18.9%	20.3%	22.9%	22.8%	16.5%	19,5%
Coors	12.1%	12.2%	12.2%	14.1%	13.6%	10.0 %	19.0 %
AmBev	21.1%	28.7%	30.5%	36.9%	35.4%		
A-B	25.9%	26.4%	27.6%	28.2%	28.8%		
Interbrew	23.3%	21.2%	21.0%	21.0%	21.3%		
Heineken	17.2%	17.1%	17.5%	17.6%	20.2%		

^{*} Years aligned for comparison purposes; CY99 to CY01 as reported in F 02 annual report under the comparable basis; CY02 and CY03 exclude gains on sales and charges for rationalization

US\$175M in synergies represent 300 basis points of margin improvement with significant opportunities for further margin expansion

Revenue	Growth Opportunities
Canada	
	Unleash Coors Light; redirect dollars from Canadian Light to Canadian
	Support value entry to regain share and drive volume savings
	Utilize the ARC technology from UK to drive on-premise listings
USA	
	Continue to support Coors Light in developmental regions, capitalizing on improving brand attribute ratings
	Expand testing of Marca Bavaria
	Leverage Molson Canadian, Zima, and Molson XXX in the complete US system
UK	
	Opportunity for Molson Lager
Brazil	
	Investigate the appeal of Coors Light
	Funding from synergies provides additional support for critical brands in key markets
	24

Enhanced Financial Strength

Pro Forma LTM Molson Coors

(US\$M)

Net sales	\$ 6,036
Operating income	694
Margin	11.5%
EBITDA	996
Margin	16.5%
Free cash flow*	723

^{*} Defined as EBITDA CAPEX

CAD/USD exchange rate of 1.34

Excludes potential synergies

LTM (last twelve months) ended June 30, 2004

Substantially enhanced financial strength, and financial flexibility

Net Debt / LTM EBITDA ratio of 1.9x

LTM Interest coverage of 7.1x

US\$175M in identified synergies

Financial strength and flexibility drives growth in revenue, profits and returns

Molson Coors A Key Strategic Step

Value Creation	Critical Mass	
Transaction unlocks shareholder value through US\$175M of merger synergies	Creates top-5 brewer with global scale and diversity	Natural strategic and cultural fit new company to combine best of both organizations
	Strong cash flow and balance	
Experienced management team can deliver upon key objectives	sheet for further investment in business and Molson Coors future growth	Vision shared by family owners who have been growing the business for generations
		Best-run global beer company

Enhanced position in consolidating global brewing industry

Q & A

Supplemental Information

Last Twelve Months Pro Forma Income Statement

			Combined		
(US\$M)	Molson	Coors	Pre-synergies	\$175M Synergies	
Net sales	1,890	4,146	6,036	6,036	
EBIT	365	331	696	871	
Margin	19.3%	8.0%	11.5%	14.4%	
EBITDA	413	585	998	1,173	
Margin	21.8%	14.1%	16.5%	19.4%	
Net income	187	174	361	475(1)	
Free cash flow*	348	377	725	900	

LTM as of June 30, 2004

CAD/USD exchange rate of 1.34

Excludes purchase accounting adjustments

(1) Synergies taxed at 35%

Margin Expansion, Stronger Cash Flow, Increased Profits

^{*} EBITDA Capex

Pro Forma Balance Sheet

(US\$M)	Molson	Coors	Combined
Cash	\$ 10.8	\$ 36.2	\$ 47.1
Total current assets	\$ 367.6	\$ 1,128.5	\$ 1,496.1
PP&E	742.3	1,411.0	2,153.3
Total assets	\$ 2,931.2	\$ 4,532.0	\$ 7,463.1
Total current liabilities	\$ 760.9	\$ 1,175.9	\$ 1,936.8
Total debt	840.6	1,142.1	1,982.7
Minority interests	93.5	29.8	123.2
Shareholders equity	929.7	1,425.4	2,355.1
Total liabilities and shareholders equity	\$ 2,931.2	\$ 4,532.0	\$ 7,463.1

As of June 30, 2004

CAD/USD exchange rate of 1.34

Excludes purchase accounting adjustments

Low leverage provides Molson Coors the financial flexibility to grow